Reporting remotely on findings presented at AACR 2020 Virtual Meeting, Grant McArthur comments on important melanoma studies.
He firstly talks about the improved response duration demonstrated by the IMspire150 trial, testing an innovative design with the addition of an anti-PD-L1 to BRAF and MEK inhibitors combination in patients with BRAF mutated, previously untreated, advanced melanoma. Secondly he discusses results of a study from the SWOG group evaluating intermittent vs continuous dosing of BRAF and MEK inhibitors in BRAF mutated melanoma. Finally he looks at results from the Keynote-555 trial about clinical outcomes on pembrolizumab 400mg Q6W dosing which is particularly interesting the COVID-19 pandemic, when keeping patients away from hospitals is needed for their safety.
- CT012 - Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial (Grant McArthur, Australia)
- CT013 - SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma (Alain Algazi, USA)
- CT042 - Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients